2家过会1家暂缓丨IPO一周要闻

Group 1: IPO Review and Approval - This week, the Beijing Stock Exchange (BSE) concluded its IPO review, with 3 companies undergoing scrutiny and 2 successfully passing the review [2] - Yongda Co., Ltd. became the first project this year to have its IPO review postponed, raising market concerns due to ongoing issues regarding the sustainability of its performance and the rationality of its fundraising projects [2] - Yongda has adjusted its fundraising plans twice during the review process, eliminating a liquidity support project and reducing the proposed investment scale for its "Heavy Chemical Equipment Production Base Phase I" project, adding uncertainty to its review [2] Group 2: Companies Approved for IPO - Kunshan Haifiman Technology Group Co., Ltd. was approved for IPO, specializing in high-end audio products under the brand "HIFIMAN," with projected revenues of 1.54 billion yuan in 2022 and a net profit of 360 million yuan [3] - Dalian Meidele Industrial Automation Co., Ltd. also received approval, focusing on intelligent manufacturing equipment, with revenues of 10.31 billion yuan in 2022 and a net profit of 2.22 billion yuan [4] Group 3: Newly Listed Companies - Hai'an Group officially listed on the Shenzhen Stock Exchange, opening with a surge of over 68%, closing at 83.52 yuan per share, with a total market value of 15.532 billion yuan [5] - Innovation Industry, an electrolytic aluminum company, debuted on the Hong Kong Stock Exchange with a first-day increase of 32.76%, focusing on alumina refining and electrolytic aluminum smelting [6] - Nant Technology saw a significant first-day increase of 183.03% on the BSE, closing at 24.51 yuan per share [7] Group 4: Companies Filing for IPO - Kewang Pharmaceutical, founded in 2017, focuses on tumor immunotherapy with a pipeline of 7 major assets, including the core product ES102, which is in clinical development [11] - Mingyu Pharmaceutical, established in 2018, has a core pipeline in the tumor field, including ADC and dual-target antibodies, with a recent valuation of 3.936 billion yuan after a financing round [12] - Baoji Pharmaceutical, founded in 2019, specializes in recombinant biopharmaceuticals and is in the clinical stage with its core pipeline KJ017, aimed at treating complex diseases [13]